Innovative Presbyopia Treatment YUVEZZI™ from Zhaoke Ophthalmology Receives Approval in Macau
Stock News
Jul 20
The innovative drug YUVEZZI™ (2.75% carbachol and 0.1% brimonidine tartrate ophthalmic solution) from Zhaoke Ophthalmology-B (06622) has received approval from the Macau Special Administrative Region's Pharmaceutical Administration for the treatment of presbyopia.
The company is actively pursuing the inclusion of YUVEZZI™ in the "Macau-Hong Kong Drug and Medical Device Access" program, with the goal of facilitating the product's clinical use in the Greater Bay Area at the earliest opportunity.
Zhaoke Ophthalmology-B is committed to providing efficient access pathways for innovative presbyopia treatment options, aiming to benefit more patients as quickly as possible.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.